Table 1.

Sites of underlying malignancies in 183 patients with Bazex syndrome.

	Until 2015a	2016–2024a, b	Total (%)
Age (mean)	62	63	63
Male/Female	144/19	13/7	157/26
Underlying Malignancies
SCCs	103	12	115 (62.8)
SCC of head & neck	67	8	75 (41.0)
SCC of esophagus	12		12 (6.6)
SCC of cervical LN MUO	11	1	12 (6.6)
SCC of lung	8	2	10 (5.5)
SCC of skin	3	1	4 (2.2)
SCC of Thymus	2		2 (1.1)
Other lung carcinoma	17	1	18 (9.8)
Other LN MTS MUO	10		10 (5.5)
Other esophagus carcinoma	8		8 (4.4)
Hematological neoplasms	4	3	7 (3.8)
Stomach	4		4 (2.2)
Colon	3		3 (1.6)
Liver	2	1	3 (1.6)
Prostate	3		3 (1.6)
Breast	3		3 (1.6)
Pancreas		2	2 (1.1)
Bile duct	1		1 (0.5)
Bladder	1		1 (0.5)
Uterus	1		1 (0.5)
Ovary	1		1 (0.5)
Thyroid		1	1 (0.5)
Neuroendcrine tumor	1		1 (0.5)
Liposarcoma	1		1 (0.5)

SCC, squamous cell carcinoma; LN, lymph node; MUO, metastasis of unknown primary; MTS, metastasis.

^aSummarized from Bolognia et al., 1991 [6] and Räßler et al., 2017 [4]. Patients selected with a detailed description of age, gender, and underlying malignancy.

^bCurrent and Present cases [[7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19]].